Ballicules.com

Dimethyl fumarate

TECFIDERA

What it isNrf2-activating immunomodulator; relapsing multiple sclerosis.

Why this oneIt is more GI-irritating than diroximel fumarate despite producing the same active metabolite.

What limits itMonitor lymphocytes because persistent lymphopenia raises PML risk. Flushing and GI upset are common.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Relapsing forms of multiple sclerosisAdult120 mg BID x7d240 mg BID240 mg BID

Titration After 7 days at starting dose, increase to maintenance.

Renal Undefined

Hepatic Undefined

Instructions

Cautions

Adverse reactions

Pregnancy Registry/observational data have not shown increased birth-defect or miscarriage risk; animal harm at high doses.

Lactation No data on presence in human milk; effects on infant/milk unknown.

NO BOXED WARNINGS

Principal riskLymphopenia raising PML risk

Cost, est. cash$300–$2,500/month

Generic entry2020

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryC

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Mechanism of action: Dimethyl fumarate ballicule

Dimethyl fumarate ballicule: receptor binding, kinetics and half-life diagram

Open Dimethyl fumarate in the interactive console ↗